← Russell 3000 cross-section

LGND LIGAND PHARMACEUTICALS INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$5.7bn
Revenue TTM
$290m
Net income TTM
$197m
Free cash flow
$131m
Composite score
50.6
Sector rank
#1003

Valuation

P / E
28.7
EV / EBITDA
42.6
EV / sales
18.7
FCF yield
2.32%
Earnings yield vs 10-yr
-1.25pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
67.9%
EBITDA margin
43.9%
ROE
20.4%
ROIC
12.9%
Revenue growth
54.9%

Insider activity, last 90 days

Net open-market
$-20.08m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our revenue is generated primarily from royalties on sales of products commercialized by our partners, supplemented by Captisol material sales and contract revenue from license fees and milestone payments. This also allows us to leverage our partner's asset infrastructure in sales and marketing, manufacturing and R&D to avoid infrastructure ourselves. 2031 Convertible Debt Financing On June 25, 2026, we completed the offering of $700.0 million aggregate principal amount of 0.00% convertible senior notes due 2031 (the “2031 Notes”). Q2 2025 Total revenue and income increased by $16.1 million, or 34%, to $63.7 million in Q2 2026 compared to $47.6 million in Q2 2025. …LIGAND PHARMACEUTICALS INC, 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →